Literature DB >> 12444031

Altered phospholipid composition and aggregate structure of lung surfactant is associated with impaired lung function in young children with respiratory infections.

Ann Mander1, Simon Langton-Hewer, Wolfgang Bernhard, John O Warner, Anthony D Postle.   

Abstract

Alterations to pulmonary surfactant structure, composition, and function contribute to the severity of respiratory infections. Analysis of bronchoalveolar lavage fluid (BALF) from children undergoing diagnostic bronchoscopy for structural abnormalities (control group, n = 24), asthma (n = 18), lung infection (n = 30), and cystic fibrosis (CF, n = 15) showed that BALF phospholipid concentration decreased with age for the control group and was elevated in all disease groups. The fractional concentration of the major surface active component, dipalmitoyl phosphatidylcholine (PC16:0/16:0), correlated (r(2) = 0.608, P < 0.01) with airway resistance (FEV(1%) predicted), and decreased PC16:0/16:0 was accompanied by increased concentrations of phospholipid components characteristic of cell membranes (PC16:0/18:1 and PI18:0/20:4). Median minimal surface tension, measured by pulsating bubble surfactometer, was elevated (P < 0.01) in both infection (17.5 mN/m) and CF (17.1 mN/m) compared with the control group (1.5 mN/m). Centrifugation (60,000 x g, 40 min) of BALF indicated that infection was accompanied by accumulation of large aggregate forms of surfactant, in contrast to previous reports of increased conversion to inactive small aggregate surfactant particles in ventilated patients with respiratory failure. This accumulation of surface-inactive, large aggregate forms of surfactant, possibly due to mixing with membrane material from inflammatory cells, may contribute to severity of lung disease in children with respiratory infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444031     DOI: 10.1165/rcmb.4746

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  14 in total

Review 1.  Surfactant and its role in the pathobiology of pulmonary infection.

Authors:  Jennifer R Glasser; Rama K Mallampalli
Journal:  Microbes Infect       Date:  2011-09-10       Impact factor: 2.700

2.  Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.

Authors:  Matthew J Wargo; Maegan J Gross; Sathish Rajamani; Jenna L Allard; Lennart K A Lundblad; Gilman B Allen; Michael L Vasil; Laurie W Leclair; Deborah A Hogan
Journal:  Am J Respir Crit Care Med       Date:  2011-05-11       Impact factor: 21.405

Review 3.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

Review 4.  Pulmonary surfactant: an immunological perspective.

Authors:  Zissis C Chroneos; Zvjezdana Sever-Chroneos; Virginia L Shepherd
Journal:  Cell Physiol Biochem       Date:  2009-12-22

5.  Lipidomic characterization and localization of phospholipids in the human lung.

Authors:  Karin A Zemski Berry; Robert C Murphy; Beata Kosmider; Robert J Mason
Journal:  J Lipid Res       Date:  2017-03-09       Impact factor: 5.922

6.  Natural lysophospholipids reduce Mycobacterium tuberculosis-induced cytotoxicity and induce anti-mycobacterial activity by a phagolysosome maturation-dependent mechanism in A549 type II alveolar epithelial cells.

Authors:  Emanuela Greco; Marilina B Santucci; Michela Sali; Francesca R De Angelis; Massimiliano Papi; Marco De Spirito; Giovanni Delogu; Vittorio Colizzi; Maurizio Fraziano
Journal:  Immunology       Date:  2009-06-22       Impact factor: 7.397

Review 7.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

8.  Lung injury, oxidative stress and fibrosis in mice following exposure to nitrogen mustard.

Authors:  Vasanthi R Sunil; Kinal N Vayas; Elena V Abramova; Raymond Rancourt; Jessica A Cervelli; Rama Malaviya; Michael Goedken; Alessandro Venosa; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2019-10-31       Impact factor: 4.219

9.  Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial.

Authors:  Cinzia Scambi; Lucia De Franceschi; Patrizia Guarini; Fabio Poli; Angela Siciliano; Patrizia Pattini; Andrea Biondani; Valentina La Verde; Oscar Bortolami; Francesco Turrini; Franco Carta; Ciro D'Orazio; Baroukh M Assael; Giovanni Faccini; Lisa M Bambara
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

Review 10.  Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota.

Authors:  Wolfgang Bernhard
Journal:  Eur J Nutr       Date:  2020-08-14       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.